The Struggles of ASX Healthcare Shares in 2026
The healthcare sector on the Australian Securities Exchange (ASX) has experienced a challenging year in 2026, with several key players facing significant declines. As of now, shares in ResMed Inc (ASX: RMD) have dropped by 21%, while Mesoblast Ltd (ASX: MSB) has fallen by 26%. Pro Medicus Ltd (ASX: PME) has seen an even steeper decline, with its share price dropping by 41% this year.
This downturn is not isolated to individual companies but reflects broader challenges within the sector. Factors such as currency fluctuations, rising labor costs, and uncertainty surrounding potential US tariffs have contributed to a negative sentiment among investors. These headwinds are particularly impactful for companies with substantial offshore operations, further exacerbating the sector’s struggles.
The S&P/ASX 200 Health Care Index (ASX: XHJ) has reached an 8-year low, with many ASX healthcare shares trading near their 52-week lows. This widespread weakness has led some analysts to believe that the current sell-off might present compelling opportunities for long-term investors who are willing to take a strategic approach.
ResMed: Steady Earnings Growth Amid Challenges
ResMed remains one of the largest and most established healthcare companies on the ASX, focusing on sleep apnea treatment and respiratory care devices. The company benefits from strong recurring revenue streams, global market leadership, and growing demand driven by aging populations and increased awareness of sleep disorders.
Despite these strengths, ResMed faces several challenges. Currency movements can affect earnings translation, and ongoing cost pressures and uncertainty around US healthcare policy remain key risks. However, analysts still see potential for growth. Morgans currently has an add rating and a $41.72 price target on ResMed, suggesting a potential upside of around 46% from current levels.
If ResMed can continue delivering steady earnings growth and healthcare sentiment improves, the recent share price weakness could prove temporary. For long-term investors, this period of volatility may offer an attractive entry point.
Mesoblast: Elevated Risks and Potential Upside
Mesoblast is one of the ASX’s most speculative healthcare shares, but it also offers potentially enormous upside if its cell therapy treatments continue to progress commercially. Investor interest in Mesoblast has largely centered around its regenerative medicine pipeline and opportunities in inflammatory disease treatment.
Biotech investing inherently carries elevated risks, including regulatory approvals, commercial execution, and funding requirements. Share price volatility can also be extreme. Despite these risks, some brokers remain optimistic. Bell Potter recently reaffirmed its speculative buy rating on Mesoblast shares and maintained a $4.45 price target, which suggests the stock could more than double in value over the next year if momentum improves and clinical progress continues.
For investors comfortable with higher risk, Mesoblast may offer significant upside leverage to positive developments.
Pro Medicus: Valuation Concerns and Long-Term Outlook
Pro Medicus has long been considered one of the ASX’s premier healthcare technology companies due to its globally respected medical imaging software platform. The company has built a strong reputation for securing major hospital contracts in the US and delivering high-margin recurring revenue growth.
However, the Pro Medicus share price has deteriorated sharply in recent months due to broader healthcare weakness and valuation concerns. Despite the sell-off, some analysts remain bullish on the company’s long-term outlook. Morgan Stanley currently maintains a buy rating on Pro Medicus shares with a 12-month price target of $200, implying potential upside of roughly 55% from current levels.
For investors seeking exposure to healthcare technology and long-term structural growth, Pro Medicus may now look far more attractive after its substantial decline.
Conclusion
While the ASX healthcare sector has faced significant headwinds in 2026, the current market conditions may present opportunities for long-term investors. Companies like ResMed, Mesoblast, and Pro Medicus each have unique strengths and challenges, offering different investment profiles. Investors should carefully consider their risk tolerance and investment goals before making any decisions.
